Alembic Pharmaceuticals arm gets tentative USFDA nod for drug to treat pulmonary arterial hypertension
The tentatively approved product is therapeutically equivalent to the reference listed drug product Remodulin injection of United Therapeutics Corp.
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Treprostinil Injection, 20 mg/20 mL (1 mg/mL), 50 mg/20 mL (2.5 mg/mL), 100 mg/20 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL), Multiple-Dose Vials. Please find enclosed herewith our press release. We request you to kindly take the same on record. Alembic Pharma (930.3): Sell
The stock of Alembic Pharmaceuticals Limited, that registered its lifetime high of 1,128.9 in early August following an astronomical rally that began Alembic Pharma share price gains 3% on USFDA nod for diabetes drugs
Alembic Pharma share trades higher 5, 50, 100 and 200-day moving averages but lower than 20-day moving averages. Stock of Alembic Pharmaceuticals has risen 3.91% in the last one month and 75% since the beginning of the year ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the Company has issued Duplicate Share Certificate(s) to the registered shareholder(s) and / or legal heir(s) of the registered shareholders on 25th August, 2020 as per details mentioned in the attached letter. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate have requested the Company for issue of duplicate share certificate.
Alembic Pharmaceuticals's JV gets USFDA nod for skin disorder treatment drug
The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product DesOwen Lotion, 0.05 percent, of Galderma Laboratories LP. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's joint venture, Aleor Dermaceuticals Limited, has received US Food and Drug Administration (USFDA) Final Approval for Desonide Lotion, 0.05%. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate of the Company has been reported as lost/misplaced and the shareholder(s) or their legal heir(s) of such lost share certificate have requested the Company for issue of duplicate share certificate for the purpose of claiming those shares from the Investor Education and Protection Fund (IEPF). We enclose herewith a letter received from Link Intime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record.